NCT06685653View on ClinicalTrials.gov

Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

Not specified

Primary Completion Date

November 30, 2026

Conditions
NSCLC
Interventions
BIOLOGICAL

Adebrelimab+RGL-270

"Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines"

BIOLOGICAL

Adebrelimab+RGL-270/single RGL-270

"Drug: Adebrelimab Adebrelimab is a programmed death-ligand 1 antibody.~Drug: RGL-270 RGL-270 is a mRNA tumor vaccines"

All Listed Sponsors
collaborator

Jilin Provincial Cancer Hospital

UNKNOWN

lead

Nanjing Tianyinshan Hospital

OTHER